Repligen Corporation

$169.44

+$5.09 (+3.10%)

Jan 5, 2026

Price History (1Y)

Analysis

Repligen Corporation is a healthcare company operating within the medical instruments and supplies industry. The company has a significant market presence with a market capitalization of $9.54B and annual revenues totaling $707.89M. Repligen's scale is substantial, employing 1778 individuals. The company's financial health is characterized by relatively low profitability margins, with gross margin at 51.6%, operating margin at 6.7%, and profit margin at 0.2%. Returns on equity (ROE) and assets (ROA) are also modest at 0.1% and 1.3%, respectively. On the balance sheet side, Repligen's debt-to-equity ratio stands at 33.07, while cash holdings amount to $748.75M against a total debt of $688.87M. Repligen's valuation context is marked by a high P/E ratio (TTM) of 8472.00 and forward P/E of 81.58. Revenue growth has been substantial, with an annual increase of 21.9%. The company does not pay dividends as indicated by the zero payout ratio.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Repligen Corporation

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Visit website →

Key Statistics

Market Cap
$9.54B
P/E Ratio
8472.00
52-Week High
$182.52
52-Week Low
$102.97
Avg Volume
833.01K
Beta
1.12

Company Info

Exchange
NMS
Country
United States
Employees
1,778